About Nucleosome assembly protein 1-like 1
Nucleosome assembly protein 1-like 1 (NAP1L1) is a protein
from Homo sapiens identified by UniProt accession
P55209, 391 residues long.
MolForge cross-references it against 0 known binders and
75 disease associations.
Target properties
| Protein name | Nucleosome assembly protein 1-like 1 |
| UniProt accession | P55209 |
| Gene | NAP1L1 |
| Organism | Homo sapiens |
| Length | 391 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (75)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin · score 0.30
- red blood cell density measurement · score 0.28
- cystatin C measurement · score 0.22
- glomerular filtration rate · score 0.14
- blood urea nitrogen measurement · score 0.14
- creatinine measurement · score 0.13
- intrathoracic organ injury · score 0.13
- amyloid-beta measurement · score 0.12
- atrial fibrillation · score 0.12
- central nervous system cancer · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P55209-F1 | alphafold | PREDICTED | 79.91 | — |
Amino-acid sequence (391 residues)
MADIDNKEQS ELDQDLDDVE EVEEEETGEE TKLKARQLTV QMMQNPQILA ALQERLDGLV ETPTGYIESL PRVVKRRVNA LKNLQVKCAQ IEAKFYEEVH DLERKYAVLY QPLFDKRFEI INAIYEPTEE ECEWKPDEED EISEELKEKA KIEDEKKDEE KEDPKGIPEF WLTVFKNVDL LSDMVQEHDE PILKHLKDIK VKFSDAGQPM SFVLEFHFEP NEYFTNEVLT KTYRMRSEPD DSDPFSFDGP EIMGCTGCQI DWKKGKNVTL KTIKKKQKHK GRGTVRTVTK TVSNDSFFNF FAPPEVPESG DLDDDAEAIL AADFEIGHFL RERIIPRSVL YFTGEAIEDD DDDYDEEGEE ADEEGEEEGD EENDPDYDPK KDQNPAECKQ Q
Explore Nucleosome assembly protein 1-like 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets